Anagrelide for Gastrointestinal Stromal Tumor

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gastrointestinal stromal tumor (GIST) is a common soft-tissue sarcoma.
• While imatinib is effective, advanced GISTs often develop resistance to tyrosine kinase inhibitors.
• Novel therapeutic targets are needed for GIST treatment.

Purpose of the Study:

• To investigate phosphodiesterase 3 (PDE3) as a potential therapeutic target in GIST.
• To evaluate the efficacy of PDE3 inhibitors in GIST cell lines and xenograft models.

Main Methods:

• Interrogated GIST gene expression in a transcriptome database.
• Studied PDE3A and PDE3B expression using immunohistochemistry on 630 human tissue samples.
• Screened GIST cell lines for sensitivity to anticancer compounds and tested PDE inhibitors in cell lines and patient-derived xenograft models.

Main Results:

• PDE3A and PDE3B were frequently expressed in GISTs compared to other tissues.
• Anagrelide emerged as a potent PDE3 modulator, reducing GIST cell viability and promoting cell death.
• Anagrelide inhibited tumor growth in GIST xenograft models, including those with challenging KIT exon 9 mutations.

Conclusions:

• PDE3A and PDE3B are frequently expressed in GIST.
• Anagrelide exhibits anticancer efficacy in GIST models.
• Anagrelide warrants further investigation in clinical trials for GIST treatment.